FDA Expands Abemaciclib Use in High-Risk Early Breast Cancer

Certain patients with high-risk early breast cancer can now receive abemaciclib (Verzenio) without needing Ki-67 testing.
Medscape Medical News

source https://www.medscape.com/viewarticle/989139?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost